Insulet (NASDAQ:PODD) Stock Lifted to "Strong-Buy" by Zacks Research

Insulet logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Zacks Research upgraded Insulet from “hold” to “strong buy.” Despite the upgrade, the broader analyst consensus remains “hold,” with an average price target of $185.04.
  • Insulet reported quarterly EPS of $1.99, beating the $1.59 estimate, and revenue of $842 million, above expectations. Revenue grew 19.2% year over year.
  • Analyst views are mixed: Raymond James maintained an “outperform” rating, while BTIG downgraded the stock to “neutral”; several other firms kept neutral or hold ratings.
  • Interested in Insulet? Here are five stocks we like better.

Insulet (NASDAQ:PODD - Get Free Report) was upgraded by investment analysts at Zacks Research from a "hold" rating to a "strong-buy" rating in a research note issued on Tuesday, Zacks reports.

A number of other research firms have also recently commented on PODD. Raymond James Financial reissued an "outperform" rating and set a $180.00 target price on shares of Insulet in a research report on Thursday, August 6th. BTIG Research downgraded shares of Insulet from a "buy" rating to a "neutral" rating in a research report on Thursday, August 6th. JPMorgan Chase & Co. lifted their target price on Insulet from $152.00 to $170.00 and gave the stock a "neutral" rating in a report on Thursday, November 5th. Truist Financial reaffirmed a "hold" rating and set a $160.00 price target (up from $153.00) on shares of Insulet in a research report on Monday, November 9th. Finally, Wells Fargo & Company lifted their target price on shares of Insulet from $144.00 to $172.00 and gave the company an "equal weight" rating in a report on Thursday, November 5th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $185.04.

Get Our Latest Stock Analysis on Insulet

Insulet Price Performance

PODD opened at $139.98 on Tuesday. Insulet has a 12-month low of $126.40 and a 12-month high of $354.88. The business's fifty day simple moving average is $142.20 and its 200-day simple moving average is $171.85. The company has a market capitalization of $9.71 billion, a price-to-earnings ratio of 22.80, a PEG ratio of 1.11 and a beta of 1.06. The company has a current ratio of 2.51, a quick ratio of 1.83 and a debt-to-equity ratio of 0.60.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.59 by $0.40. The company had revenue of $842.00 million for the quarter, compared to analysts' expectations of $832.63 million. Insulet had a net margin of 13.44% and a return on equity of 31.76%. The firm's quarterly revenue was up 19.2% on a year-over-year basis. During the same period in the prior year, the business earned $1.24 EPS. On average, equities research analysts anticipate that Insulet will post 6.76 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. OneDigital Investment Advisors LLC acquired a new position in Insulet during the second quarter worth $6,741,000. Headlands Technologies LLC raised its stake in shares of Insulet by 2,041.5% in the 2nd quarter. Headlands Technologies LLC now owns 31,930 shares of the medical instruments supplier's stock valued at $4,861,000 after acquiring an additional 30,439 shares during the period. Amundi lifted its stake in Insulet by 13.6% during the second quarter. Amundi now owns 507,847 shares of the medical instruments supplier's stock worth $77,320,000 after purchasing an additional 60,929 shares in the last quarter. Man Group plc acquired a new position in Insulet during the 2nd quarter worth about $78,746,000. Finally, Deutsche Bank AG purchased a new position in shares of Insulet in the second quarter valued at approximately $51,153,000.

Insulet Company Profile

(Get Free Report)

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.

Further Reading

Analyst Recommendations for Insulet (NASDAQ:PODD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Insulet Right Now?

Before you consider Insulet, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.

While Insulet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines